SEC Form 4 · accession 0001225208-17-017780
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael P. Phalen
Officer — EVP & President, MedSurg
Period of report
Nov 29, 2017
Accepted (ET)
Nov 30, 2017 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 10, 2017 | G | 4,756 | $0.00 | D | 97,910 | D | |
| Common StockF1 | Nov 29, 2017 | M | 15,500 | $7.16 | A | 113,410 | D | |
| Common StockF3,F1 | Nov 29, 2017 | S | 15,500 | $26.6614 | D | 97,910 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $7.16 | Nov 29, 2017 | M | 15,500 | D | — | Feb 28, 2021 | Common Stock | 15,500 | 15,835 | D |
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F3Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.6210 to $26.72, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.